Skip to content
Sunday 16 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Product/Service

  • Motive Launches AI Dashcam Plus, Powering a New Era of Edge AI Safety for Physical Operations

    January 8, 2026

    New commercial vehicle AI dash cam delivers three times more AI processing power, stereo vision, and hands-free two-way communication in an all-in-one device Powered by the Qualcomm Dragonwing QCS6490 processor, AI Dashcam Plus can run more than 30 AI models simultaneously and is designed to detect and respond to risk instantly

  • Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base

    January 8, 2026

    Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics. “With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, [...]

  • Chromavis Implements Transparency-One® to Help Strengthen Supply Chain Traceability and Sustainability Initiatives

    January 7, 2026

    Leading cosmetics manufacturer leverages Transparency-One to deepen visibility across global supplier networks

  • OneSource Virtual Announces Strategic, Majority Growth Investment from TA

    January 7, 2026

    OneSource Virtual (OSV), a leading provider of HR and payments services for the Workday ecosystem, today announced a strategic, majority growth investment from TA Associates (TA), a leading global private equity firm. This investment will support the continuation of OSV’s organic growth, product innovation, and enhanced customer capabilities across the Workday ecosystem. This press release [...]

  • Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

    January 7, 2026

    The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease

  • CCC Digital Key™ Certifications Surged in 2025, Reinforcing the Global Standard for Secure Vehicle Access

    January 6, 2026

    115 vehicle and module products achieved CCC Digital Key™ certification, including the first certified vehicles in China

  • Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence

    January 6, 2026

    Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment [...]

  • Paris Saint-Germain Partners With Zing Coach Until 2027 to Encourage Fans to Get Active Through Interactive Fitness Experiences

    January 6, 2026

    Paris Saint-Germain’s global fanbase will be offered the chance to engage in training routines modeled after their favorite Women and Men star players through Zing Coach’s AI-powered fitness platform, with top performers receiving exclusive experiences and prizes

  • Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology

    January 6, 2026

    Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease

  • Iksuda to Present Preliminary Analysis of Oesophageal Cancer Data From Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium

    January 6, 2026

    Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy that included a trastuzumab component in at least one prior treatment

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 86
  • Page 87
  • Page 88
  • Page 89
  • Page 90
  • …
  • Page 113
  • Next

Trending Articles

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut takes flight with launch of new airport lounges

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook